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Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging
pathogen causing chronic pulmonary infection in cystic ﬁbrosis (CF). We compare
the the innate immune response induced by the ﬁrst MRSA recovered in a CF-
patient and the corresponding isogenic strain obtained 13 years after.
Material and Methods: 36 MRSA isolates were obtained from a single CF-patient
along 13 years (1996–2009). Genetic diversity was analyzed by PFGE-XbaI and
MLST. Immunogenic ability was determined in parallel in two isogenic strains
corresponding to the ﬁrst and the last isolates obtained (CF-MRSA-1996 and CF-
MRSA-2009) and compared with the HARMONY ST245-MRSA reference strain.
Puriﬁed human peripheral blood monocytes, isolated from healthy volunteers, were
incubated with freshly prepared sonicated crude extracts of both CF-strains for 3
and 6 h. Then, TREM-1, TNF-a, IL-6, IL-12, IL-10 and IRAK-M expression were
analyzed at both mRNA and protein levels using real-time quantitative PCR, Flow
Cytometry and Western blot.
Results: All MRSA isolates were almost genetically identical and belonged to
the ST245-SCCmecI-pvl−. CF-MRSA-2009 provoked 50% less pro-inﬂammatory
response in cultures of human monocytes than the isogenic CF-1996-MRSA isolate
and also less than the reference strain. However, the pro-inﬂammatory response
with the reference strain was 1.5 times higher when compared with both CF-MRSA
isolates.
Conclusion: Chronic colonization of a single ST247-SCCmecI-MRSA clone de-
termines an attenuation process of triggering the human innate immune system.
This observation might explain the tolerance of the host towards Staphylococcus
observed in CF patients.
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Cystic ﬁbrosis patients often acquire a chronic Pseudomonas aeruginosa lung
infection. The adaptive immune response is characterised by a Th2 dominated
response with a pronounced antibody production. However, patients with a more
Th1 dominated response have a better lung function. To further investigate the role
of the adaptive immune response we aimed at characterising the dendritic cells
(DCs) in a mouse model of chromic P. aeruginosa lung infection.
P. aeruginosa (PAO579) were embedded in seaweed alginate beads (0.7×109
CFU/ml). Female BALB/c (n = 35) were infected with 0.04ml of the beads in
the left lung. Mice were killed 1, 2, 3, 7 or 10 days after infection. Lungs and
regional lymph nodes were collected. DCs were enriched by magnetic cell sorting
with anti-CD11c from mechanically degraded lungs and regional lymph nodes. DCs
were deﬁned as CD11c+ and MHCII+ CD45+ cells and analysed by ﬂow cytometry.
Numbers of DCs were determined using Truecount (R&D) and presented as median
log number/ml.
In the lungs a rise in the number of DCs were detected from day 1 [5.49 (5.12–
6.14)] to day 2 [6.24 (6.15–6.54), p 0.02). From day 3 [5.83 (5.62–6.15)] to day 7
[6.38 (6.27–6.47)] a further increase in DCs was observed (p = 0.02). However, at
day 10 DCs decreased [6.05 (5.67–6.23), p = 0.05]. In the regional lymph nodes
DCs increased from day 1 [4.64 (4.09−5.2)] to day 3 [5.83 (5.79–6.15), p< 0.02].
Lymph DCs remained stable through day 7 [6.52 (5.73–6.54)] but decreased at
day 10 [5.15 (5.06–5.26), p< 0.02].
In conclusion, the present study shows a signiﬁcant increase in the DCs during
chronic P. aeruginosa lung infection, indicating that DCs may be subject to immune
modulatory treatment.
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IL-17A is a neutrophil attracting cytokine that plays a role in the pathogenesis
of numerous diseases, including the pathophysiology of lung inﬂammation in
CF patients. IL-17A is produced by different types of T cell populations, such
as CD4 positive T helper 17 cells (Th17 cells) and natural killer T (NKT) cells.
However, T cells are not the only source of this cytokine. Neutrophils in the broncho-
alveolar lavage ﬂuid of severe combined immunodeﬁciency (SCID) mice are also
able to produce IL-17 upon LPS stimulation [1]. Since sputum of CF patients
contains numerous neutrophils as well as high IL-17 levels, we hypothesized that
these neutrophils could be a main source of IL-17 production.
We collected induced sputum samples of two adult CF patients. Cytospins were
performed on lysine-coated glass slides. Unspeciﬁc binding sites were priorly
blocked and IL-17 was immunodetected on permeabilized cells by immunoﬂu-
orescence using a monoclonal antibody against human IL-17A and an Alexa-
Fluor 488 ﬂuorochrome-conjugated secondary antibody. Nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI).
Neutrophils in the sputum of both CF patients were positive for IL-17A.
These preliminary data show that IL-17 is produced by neutrophils in the sputum
of CF patients, suggesting that IL17 might play a role in maintaining continued
presence of neutrophils, responsible of lung tissue destruction in CF.
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Antigen-speciﬁc T-cells are involved in the pathogenesis of sulfamethoxazole
(SMX) hypersensitivity. The aim of this study was to utilize lymphocytes from
SMX hypersensitive patients with and without cystic ﬁbrosis (CF) to explore the
chemical basis of drug-speciﬁc T-cell activation. Lymphocytes (1.5× 105; 200ml)
from 6 patients (3 with CF) were stimulated to proliferate when incubated with
SMX (100mg/ml; SI range 2−15) and nitroso SMX (80 mM; SI range 2−28). Over
5000 T-cell clones were generated from the hypersensitive patients and studied
in terms of their antigen-speciﬁcity. 98 clones were stimulated with SMX (50–
200mg/ml; SI range 2−39, 66% CD4+, 21% CD8+, and 11% dual positive), while
154 clones proliferated in the presence of nitroso SMX (20–160mM; SI range
2−49, 87% CD4+, 10% CD8+ and 3% dual positive). In patients without CF,
SMX stimulated T-cells via a direct interaction with MHC molecules. Nitroso SMX
stimulated T-cells by (1) binding irreversibly to MHC and (2) a classical hapten
mechanism involving antigen processing. In contrast, T-cell clones from patients
with CF were stimulated with both SMX and nitroso SMX. The response to SMX
was dependent on metabolism by antigen presenting cells (APC) and intracellular
adduct formation. The SMX-speciﬁc proliferative response was inhibited by the
enzyme inhibitors methimazole and 1-aminobenzotriazole. Furthermore, pulsing
APC for 16 h generated an antigenic signal for T-cells. These results demonstrate
that intracellular SMX metabolism by immune cells and subsequent protein adduct
formation represents an important antigenic signal in hypersensitive patients with
CF.
